Introduction to a Pivotal Gene Therapy Study
On October 30, 2023, a significant clinical trial commenced, focusing on LY-M001, a gene therapy drug for Gaucher Disease Type I. This trial is particularly noteworthy for its involvement of PackGene as the CMC (Chemistry, Manufacturing, and Controls) service provider, ensuring stringent quality and regulatory compliance in the drug’s production.
Study Details
The LY-M001 clinical trial is a prospective, single-center, open-label, single-arm interventional study. Its purpose is to evaluate the safety, initial efficacy, pharmacodynamic characteristics, immunogenicity, biodistribution, and viral shedding of a single intravenous infusion of LY-M001. PackGene’s role as the CMC service provider underscores the trial’s commitment to high-quality standards in gene therapy research.
Phases of the Study
The study is structured into several distinct phases:
- Screening Period (Weeks -8 to Days -2): Pre-eligibility assessment.
Baseline Period (Day -1): Establishment of health benchmarks before treatment. - Treatment and Safety Observation Period (Days 0 to 28): Administration of LY-M001 and monitoring for safety and immediate effects.
- Short-Term Follow-Up Period (Weeks 5 to 38): Assessment of the treatment’s short-term impact.
- Participants are required to complete all assessments for the End of Study (EOS) visit, regardless of whether they complete the study or withdraw early.
- The initial dose group is set at 5.0 × 10^12 vg/kg, following a sentinel method for participant enrollment and observation.
Long-Term Follow-Up Study
This study also includes a long-term follow-up phase lasting a total of 5 years, essential for understanding the prolonged effects and safety of LY-M001.
Study Specifications
- Study Type: Interventional (Clinical Trial)
- Estimated Enrollment: 3 participants
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Official Title: Prospective, Single-center, Open-arm, Single-arm Study of Safety and Preliminary Efficacy of LY-M001 Injection
- Start Date: October 30, 2023
- Primary Completion Date: August 17, 2024
- Study Completion Date: October 17, 2028
The Role of PackGene
PackGene’s involvement as the CMC service provider is a testament to the trial’s emphasis on quality and regulatory adherence in drug development. This collaboration is anticipated to play a crucial role in the successful execution of the trial and in potentially setting new benchmarks in gene therapy treatments for Gaucher Disease Type I.
Conclusion
This clinical trial, with PackGene’s support, represents a significant step in the advancement of gene therapy for Gaucher Disease Type I. The thorough approach to the study’s design and execution reflects an unwavering commitment to exploring innovative treatments in the field of medical science.
1. https://classic.clinicaltrials.gov/ct2/show/NCT06162338
2. https://mp.weixin.qq.com/s?__biz=MzkxNDMwMzgyNg==&mid=2247484148&idx=1&sn=42b9e305013074992c5f03949c2563ae
![GMP mRNA](https://static.packgene.com/wp-content/uploads/2023/07/13.jpg)
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Skyline Therapeutics Receives FDA Orphan Drug Designation for Gene Therapy for Retinitis Pigmentosa
BOSTON & SHANGHAI, September 2, 2024 – Skyline Therapeutics, a gene therapy company focused on innovative treatments for rare and severe diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SKG1108....
Novavax Receives Emergency Use Authorization for Updated Covid-19 Vaccine
Novavax has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its updated Covid-19 vaccine, NVX-CoV2705, joining other vaccine manufacturers in addressing evolving virus variants. The EUA permits the use of Novavax's...
Turn Biotechnologies Reports Historic Skin Cell Rejuvenation Breakthroughs at ESDR this Week
Company will present data from its successful rejuvenation of fibroblasts and keratinocytes to influential gathering of international dermatologists MOUNTAIN VIEW, Calif., Sept. 4, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and...
H5 influenza vaccines: What needs to be done to reduce the risk of a pandemic
As the global threat of H5N1 influenza looms with outbreaks across species and continents including the U.S., three international vaccine and public health experts say it is time to fully resource and support a robust strategy to address this and future potential...
Related Services
![](https://static.packgene.com/wp-content/uploads/2023/01/9-1.png)
Plasmids GMP Services
![](https://static.packgene.com/wp-content/uploads/2023/01/10-2.png)
AAV GMP Services
![aav icon](https://static.packgene.com/wp-content/uploads/2023/01/9-1.png)